Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of ischemic cerebrovascular and cardiovascular events with terutroban vs aspirin after ischemic stroke or transient ischemic attack
2005-003700-10Phase 3Completed
- Sponsor
- Servier
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of terutroban in ischemic stroke, transient ischaemic attack (TIA), myocardial infarction (MI) and 2 more (2 arms), sponsored by Servier. Primary endpoint: Composite primary efficacy endpoint. Started Nov 2005; status: completed.
02
Drugs
terutroban
03
Conditions
ischemic stroketransient ischaemic attack (TIA)myocardial infarction (MI)cerebrovascular diseasecardiac morbidity
Beyond the preview
Go deeper on 2005-003700-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003700-10.